Ponatinib: New option for the treatment of adults with CML or PH+ all that is resistant or intolerant to previous therapy with tyrosine kinase inhibitors

American Health and Drug Benefits

Volumn 6, Issue 1 SPL, 2013, Pages

  Lederman, Lynne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CYTOCHROME P450 3A INHIBITOR; DASATINIB; ENZYME INHIBITOR; EPHRIN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANEMIA; ARTERY THROMBOSIS; ARTHRALGIA; BLEEDING; BONE MARROW; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PROGNOSIS; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; DEATH; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEVER; GENE MUTATION; HEADACHE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFECTION; LEUKOCYTE; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; NOTE; OCCLUSIVE CEREBROVASCULAR DISEASE; PALLOR; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; RASH; RECIPROCAL CHROMOSOME TRANSLOCATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN BRUISING; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84875047036     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. Cortez JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075-2088.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Version 3.2013. NCCN.org. Accessed December 19, 2012.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute lymphoblastic leukemia. Version 2.2012. NCCN.org. Accessed: January 9, 2013.
5. Carella AM, Goldman JM, Martinelli G, et al. Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica. 2011;96:1737-1739.
6. Goldman JM. Ponatinib for chronic myeloid leukemia. N Engl J Med. 2012;367:2148-2149.
7. ARIAD Pharmaceuticals. ARIAD announces accelerated approval by FDA of Iclusig (ponatinib) for patients with CML and Ph+ ALL resistant or intolerant to prior tyrosine kinase inhibitor therapy. December 14, 2012. http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle_print&ID=1767523&highlight=. Accessed January 17, 2013.
8. FDA News Release. FDA approves Iclusig to treat two rare types of leukemia. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm. Accessed January 17, 2013.
9. Iclusig (ponatinib) tablets for oral use. Prescribing information. ARIAD Pharmaceuticals, Inc: Cambridge, MA; December 2012.
10. O'Hare T, Shakespeare WC, Zhu X, et al. AP24535, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401-412.
11. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. J Clin Oncol. 2012; 30(suppl):Abstract 6503.
12. Cortes J, Kim DW, Pinilla J, et al. PACE: a pivotal phase 2 trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Haematologica. 2012; 97(suppl 1):453.
13. ARIAD EPIC PR. ARIAD announced initiation of randomized phase 3 trial of ponatinib in newly diagnosed patients with chronic myeloid leukemia. http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1719432&highlight=. Accessed January 17, 2013.